Insider · CIK 0001573327
Karthik Radhakrishnan
Files at MNPR (Monopar Therapeutics). First filing Oct 30, 2024, latest Oct 30, 2024.
Karthik Radhakrishnan files SEC Form 4 as CFO at MNPR (Monopar Therapeutics). Since Oct 30, 2024, Karthik Radhakrishnan has reported 1 open-market buy worth $25k and 0 open-market sells worth $0, the latest filed on Oct 30, 2024.
A track record needs three past buys with six months of prices behind them; Karthik Radhakrishnan has 0, so none is measured yet.
The newest scored trade: bought $25k of MNPR on Oct 28, 2024, filed Oct 30, 2024, scored 35 (weak).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
MNPR: Monopar Therapeutics
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 1 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 28, 2024 | MNPR Monopar Therapeutics | POpen-market purchase Common Stock | +1,550 | $16.25 | $25k | 1,550 | Oct 30, 2024 |
Questions about Karthik Radhakrishnan
Answered from the filings on this page, as of the latest one.
Is Karthik Radhakrishnan buying or selling?
Not in the last 12 months. Karthik Radhakrishnan's latest open-market trade on SEC Form 4 was bought $25k of MNPR on Oct 28, 2024.
How did Karthik Radhakrishnan's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Karthik Radhakrishnan has 0.
Where does Karthik Radhakrishnan file Form 4?
Karthik Radhakrishnan has filed Form 4 at MNPR (Monopar Therapeutics) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.